Literature DB >> 24183862

Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs.

Eva M Bongers1, Angela Botticella, David A Palma, Cornelis J A Haasbeek, Andrew Warner, Wilko F A R Verbakel, Ben Slotman, Umberto Ricardi, Suresh Senan.   

Abstract

PURPOSE: To identify dosimetric factors that predict development of radiation pneumonitis (RP) following stereotactic or hypofractionated radiotherapy for lung tumors.
METHODS: Seventy-nine consecutive patients with either a planning target volume (PTV)>100 cm(3) (n=69) or prior pneumonectomy or bi-lobectomy (n=13) were identified. Radiation doses (range: 5-50 Gy, with 5 Gy increments) were converted to equivalent doses (EQD(2 Gy)) (α/β=3). Total lung (TL), ipsilateral (IL) and contralateral lung (CL) volumes minus PTV, receiving 5 Gy (V5) up to 50 Gy (V50) and mean lung dose (MLD) were analyzed. Predictors of grade ≥3 RP (CTCAEv4.03) were identified with concordance-statistics (C-statistic) and p-values used to quantify the performance of the model. Factors found to be significant were entered into a recursive partitioning analysis (RPA).
RESULTS: Median PTV was 150 cm(3). Grade ≥3 RP was observed in 8 patients (10%). In univariable analysis, CL-MLD, CL-V5-15, TL-MLD, TL-V5-V10 and ITV size were predictive of RP (p<0.05). In multivariable analysis, contralateral MLD (p=.007) and ITV (p=.063) were the strongest predictors of grade ≥3 RP, with excellent discrimination (C-statistic: 0.868).
CONCLUSION: Contralateral MLD and ITV size are both strong predictors of grade ≥3 RP post treatment. Planning constraints should aim to keep contralateral MLD below 3.6 Gy.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Lung tumors; Radiation pneumonitis; Stereotactic radiotherapy

Mesh:

Year:  2013        PMID: 24183862     DOI: 10.1016/j.radonc.2013.10.011

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  19 in total

Review 1.  Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer.

Authors:  Joshua D Palmer; Nicholas G Zaorsky; Matthew Witek; Bo Lu
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  Optimizing the flattening filter free beam selection in RapidArc®-based stereotactic body radiotherapy for Stage I lung cancer.

Authors:  J-Y Lu; Z Lin; P-X Lin; B-T Huang
Journal:  Br J Radiol       Date:  2015-07-02       Impact factor: 3.039

3.  Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection.

Authors:  Jason T Hayes; Elizabeth A David; LiHong Qi; Allen M Chen; Megan E Daly
Journal:  Clin Lung Cancer       Date:  2015-01-31       Impact factor: 4.785

4.  Timing and characteristics of radiation pneumonitis after stereotactic body radiotherapy for peripherally located stage I lung cancer.

Authors:  Ayae Kanemoto; Yasuo Matsumoto; Tadashi Sugita
Journal:  Int J Clin Oncol       Date:  2014-11-07       Impact factor: 3.402

5.  Risk factors for radiation pneumonitis after stereotactic radiation therapy for lung tumours: clinical usefulness of the planning target volume to total lung volume ratio.

Authors:  Tomoko Ueyama; Takeshi Arimura; Koji Takumi; Fumihiko Nakamura; Ryutaro Higashi; Soichiro Ito; Yoshihiko Fukukura; Tomokazu Umanodan; Masanori Nakajo; Chihaya Koriyama; Takashi Yoshiura
Journal:  Br J Radiol       Date:  2018-04-16       Impact factor: 3.039

Review 6.  Stereotactic radiotherapy for early stage non-small cell lung cancer.

Authors:  Umberto Ricardi; Serena Badellino; Andrea Riccardo Filippi
Journal:  Radiat Oncol J       Date:  2015-06-30

7.  Comparison of Two RapidArc Delivery Strategies in Stereotactic Body Radiotherapy of Peripheral Lung Cancer with Flattening Filter Free Beams.

Authors:  Bao-Tian Huang; Jia-Yang Lu; Pei-Xian Lin; Jian-Zhou Chen; Yu Kuang; Chuang-Zhen Chen
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

8.  Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy.

Authors:  Bao-Tian Huang; Jia-Yang Lu; Pei-Xian Lin; Jian-Zhou Chen; De-Rui Li; Chuang-Zhen Chen
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

9.  Focal exposure of limited lung volumes to high-dose irradiation down-regulated organ development-related functions and up-regulated the immune response in mouse pulmonary tissues.

Authors:  Bu-Yeo Kim; Hee Jin; Yoon-Jin Lee; Ga-Young Kang; Jaeho Cho; Yun-Sil Lee
Journal:  BMC Genet       Date:  2016-01-27       Impact factor: 2.797

10.  Harmonization of breast cancer radiotherapy treatment planning in the Netherlands.

Authors:  Coen Hurkmans; Cindy Duisters; Mieke Peters-Verhoeven; Liesbeth Boersma; Karolien Verhoeven; Nina Bijker; Koen Crama; Tonnis Nuver; Maurice van der Sangen
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.